Effect of aldose reductase inhibition on resistance to ischemic conduction block in diabetic subjects.
Diabetes Care
; 14(5): 411-3, 1991 May.
Article
em En
| MEDLINE
| ID: mdl-1905621
ABSTRACT
OBJECTIVE:
To study the effect of aldose reductase inhibition with ponalrestat on resistance to ischemic conduction block (RICB) in diabetic subjects. RESEARCH DESIGN ANDMETHODS:
Twenty-one healthy diabetic subjects without neuropathy were studied. Subjects were randomized to take either a double-blind trial of 600 mg ponalrestat or placebo once daily for 6 wk. The median nerve action potential (MNAP) and conduction velocity (NCV), before and after 20 min of forearm ischemia, were measured at the start and finish of the study.RESULTS:
RICB (MNAP remaining after ischemia) decreased from 39.5 to 29.4% in the ponalrestat-treated group (P less than 0.05) and increased from 48.1 +/- 10.2 to 49.5 +/- 6.5% in the placebo-treated group. MNAP and NCV were unchanged in both groups.CONCLUSIONS:
Aldose reductase inhibition with ponalrestat partly reverses RICB in diabetes, perhaps by improving nerve hypoxia or reducing nerve energy substrates.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ftalazinas
/
Aldeído Redutase
/
Diabetes Mellitus
/
Hipoglicemiantes
/
Isquemia
/
Nervo Mediano
/
Condução Nervosa
Tipo de estudo:
Clinical_trials
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
1991
Tipo de documento:
Article